IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.

Zacks Investment Research • May 28, 2026

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceutic.

Business Wire • May 28, 2026

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

Business Wire • May 27, 2026

Ironwood Pharmaceuticals: A Contrarian Buy Opportunity

Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.

Seeking Alpha • May 22, 2026

Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due

Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.

Seeking Alpha • May 13, 2026

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).

MarketBeat • May 8, 2026

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

Zacks Investment Research • May 8, 2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance. “Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-y.

Business Wire • May 7, 2026

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.14 per share a year ago.

Zacks Investment Research • May 7, 2026